The sale decreases Pfizer’s shareholding in the consumer-healthcare business to 7.3% of its issued share capital, down from 15%.

Pfizer divests $3.05 billion of Haleon shares, cutting its stake to 7.3% in a strategic shift to refocus on core pharmaceutical operations.

Pfizer will sell shares worth 2.50 billion pounds ($3.05 billion) in Haleon, lowering its stake in the British consumer ...

Pfizer is unloading a significant part of its holdings in Haleon, the Advil manufacturer formed in 2022 out of the former consumer-health divisions of Pfizer and GSK. In a two-part deal that could ...

Pfizer sold shares of Haleon last year, including a £2.4 billion overnight sale in the autumn. Haleon was formed in 2022 from a combination of GSK Plc and Pfizer’s consumer-health units.

Based in the United Kingdom, Haleon makes consumer health care products, including Advil, Centrum Multivitamin and Aquafresh ...

Haleon said in a prospectus filed earlier this week that it could face "possible liabilities" connected with OTC Zantac, although it is in the midst of indemnity negotiations with GSK and Pfizer ...

The UK pharma group – now a therapeutics and vaccines pure-play since the spin-off of Haleon ... adults. GSK is trying to bring its vaccine to market ahead of a rival jab from Pfizer, which ...

The UK-based consumer healthcare company will be modernizing its facility along Brook Road, where it conducts R&D for such ...

Haleon--which owns brands such as Sensodyne toothpaste, Aquafresh mouthwash and over-the-counter medicines Panadol and Advil--was formed in July 2019 through the merger of GSK and Pfizer's ...

The sale represents nearly 7.7% of the issued share capital of Haleon, which was created by the merger of GSK and Pfizer's consumer healthcare businesses in 2019. It was spun off from the British ...